Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (31-40 of 493) with videos related to

Pageof 50
Sort By:
Expert Opinion on Emerging Drugs|August 20, 2016
Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)Michael B Atkins, George K Philips
Current Urology Reports|December 22, 2004
Chemotherapies and immunotherapies for metastatic kidney cancerYoo-Joung Ko, Michael B Atkins
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Geoffrey T Gibney, Michael B Atkins
Blood|October 1, 1995
Comparative responsiveness of HL-60, HL-60R, and HL-60R+ (LRARSN) cells to retinoic acid, calcitriol, 9 cis-retinoic acid, and sodium butyrateK B Atkins, B R Troen
Expert Review of Anticancer Therapy|May 19, 2009
Molecular-targeted therapy in malignant melanomaRyan J Sullivan, Michael B Atkins
The Lancet. Oncology|October 3, 2009
Resistance to targeted therapy in renal-cell carcinomaBrian I Rini, Michael B Atkins
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
Immunotherapeutic approaches for the treatment of malignant melanomaC Curiel-Lewandrowski, M B Atkins
Seminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B Atkins
Nature Reviews. Clinical Oncology|November 28, 2009
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?Toni K Choueiri, Michael B Atkins
Pageof 50

Showing results (31-40 of 493) with videos related to

Sort By:
Pageof 50
Expert Opinion on Emerging Drugs|August 20, 2016
Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)Michael B Atkins, George K Philips
Current Urology Reports|December 22, 2004
Chemotherapies and immunotherapies for metastatic kidney cancerYoo-Joung Ko, Michael B Atkins
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Geoffrey T Gibney, Michael B Atkins
Blood|October 1, 1995
Comparative responsiveness of HL-60, HL-60R, and HL-60R+ (LRARSN) cells to retinoic acid, calcitriol, 9 cis-retinoic acid, and sodium butyrateK B Atkins, B R Troen
Expert Review of Anticancer Therapy|May 19, 2009
Molecular-targeted therapy in malignant melanomaRyan J Sullivan, Michael B Atkins
The Lancet. Oncology|October 3, 2009
Resistance to targeted therapy in renal-cell carcinomaBrian I Rini, Michael B Atkins
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
Immunotherapeutic approaches for the treatment of malignant melanomaC Curiel-Lewandrowski, M B Atkins
Seminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B Atkins
Nature Reviews. Clinical Oncology|November 28, 2009
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?Toni K Choueiri, Michael B Atkins
Pageof 50